بررسی نوروهورمون ها در الگوی خواب بیماران مبتلا به سندرم تخمدان پلی کیستیک

نوع مقاله: اصیل پژوهشی

نویسندگان

1 استادیار مرکز تحقیقات بهداشت باروری ولیعصر(عج)، بیمارستان ولیعصر(عج)، مجتمع بیمارستانی امام خمینی، دانشگاه علوم پزشکی تهران، تهران، ایران.

2 مربی گروه پزشکی اجتماعی، دانشکده پزشکی، دانشگاه علوم پزشکی فسا، فسا، ایران.

3 استادیار گروه پاتولوژی، دانشکده پزشکی، آزمایشگاه پاتولوژی بیمارستان ولیعصر(عج)، مجتمع بیمارستانی امام خمینی، دانشگاه علوم پزشکی تهران، تهران، ایران.

4 کارشناس ارشد مامایی، مرکز بهداشت باروری ولیعصر(عج)، بیمارستان ولیعصر(عج)، مجتمع بیمارستانی امام خمینی، دانشگاه علوم پزشکی تهران، تهران، ایران.

چکیده

مقدمه: انسان تقریباً یک سوم از زندگی خود را در خواب می گذراند، اما هنوز عملکرد این رفتار به خوبی شناخته نشده است .مطالعه حاضر با هدف بررسی نقش دو سویه بین خواب و فرآیند هورمونی دو محور هیپوفیز-هیپوتالاموس-آدرنال و گنادال در بیماران مبتلا به تخمدان پلی کیستیک انجام شده است.
روش کار: این مطالعه موردی- شاهدی در سال 1391 بر روی 77 بیمار مبتلا به سندرم تخمدان پلی کیستیک در مرکز تحقیقات بهداشت باروری ولیعصر بیمارستان امام خمینی تهران انجام شد. در این مطالعۀ، سطوح سرمی نوروهورمون های استرس، بتا اندورفین، خواب و پروژسترون در 77 بیمار مبتلا به تخمدان پلی کیستیک و 97 زن سالم سنجیده شد. بررسی الگوی خواب توسط پرسشنامه کیفیت خواب پیتزبورگ PSQI در دو گروه انجام شد. تجزیه و تحلیل داده ها با استفاده از نرم افزار آماری SPSS (نسخه 18) و آزمون های کای دو، کولموگروف اسمیرنوف تی، من ویتنی، ضریب همبستگی پیرسون، اسپیرمن و تحلیل رگرسیونی انجام شد. میزان p کمتر از 05/0 معنی دار در نظر گرفته شد.
یافته ها: سطح سرمی هورمون های استرس آدرنالین و نورآدرنالین در گروه PCO که زودتر به خواب می‌رفتند (54/2±88/3) به طور معنی داری کمتر از افرادی در همین گروه بود که دیرتر به خواب می‌رفتند (71/4±43/6) (041/0=p). هورمون بتا اندورفین (001/0=p) و ملاتونین (031/0=p) در گروه PCO کمتر از گروه کنترل بود. بر اساس نتایج تحلیل رگرسیونی، در گروه بیماران فقط کورتیزول با امتیاز کیفیت خواب ارتباط معنی داری داشت (023/0=p).
نتیجه گیری: بیمارانی که شب دیر خوابیده و صبح نیز دیر بیدار می شوند، سطوح نوروهورمون های آدرنالین، نورآدرنالین، ملاتونین و بتااندورفین در آنها کاهش معنی داری دارد.

کلیدواژه‌ها


عنوان مقاله [English]

Evaluation of Neurohormones in sleep pattern of patients with polycystic ovary syndrome

نویسندگان [English]

  • Farideh Zangeneh 1
  • Mohamad Mehdi Naghizadeh 2
  • Alireza Abdollahi 3
  • Maryam Bagheri 4
1 Assistant Professor, Vali-e-Asr Reproductive Health Research Center, Vali-e-Asr Hospital, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
2 Lecture, Department of Community Medicine, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran.
3 Assistant Professor, Department of Pathology, School of Medicine, Pathology laboratory of Vali-e-Asr Hospital, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
4 M.Sc. of Midwifery, Vali-e-Asr Reproductive Health Research Center, Vali-e-Asr Hospital, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
چکیده [English]

Introduction: Human spends approximately one third of their live in sleeping, but still the function of this behavior is not well understood. This study was performed with the aim to evaluate the double role of sleep and hormonal process of two axis of hypothalamus-pituitary-adrenal and gonadal in patients with polycystic ovary syndrome (PCO).
Methods: this case-control study was performed on 77 patients with PCO in Vali-e-Asr Reproductive Health Research Center of Imam Khomeini Hospital at 2012. In this study, serum levels of stress neurohormones, beta-endorphin, progesterone and sleep were evaluated in 77 patients with polycystic ovarian syndrome and 97 healthy women. Sleep patterns were evaluated in two groups by the questionnaire of Pittsburgh Sleep Quality Index PSQI. Analysis of data was performed using statistical software SPSS (version 18) and chi-square, Kolmogorov-Smirnov test, Mann-Whitney, Pearson, Spearman and regression analysis. PResults: Serum levels of stress hormones of adrenaline and noradrenaline in the PCO group who sleep earlier (3.88 ± 2.54) was significantly lower than those in the same group who sleep later (6.43 ± 4.71 (P=0.041). Level of beta-endorphin (P=0.001), and melatonin in the PCO group was lower than the control group. Regression analysis showed that in patients group, only cortisol levels showed a significant relationship with sleep quality scores (P=0.023).
Conclusion: the neurohormonal levels of Adrenaline, Noradrenaline, Melatonin and Betaendorphine are significantly reduced in the patients who sleep late at night and wake up late in the morning.

کلیدواژه‌ها [English]

  • Beta-endorphin
  • Melatonin
  • Polycystic ovary (PCO)
  • Progesterone
  • Sleep
  • Stress hormones
  1. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Na Rev Neurosci. 2007; 8: 171-181.
  2. Neil R. Carlson. Foundations of Physiological Psychology. Translator: M. Peghan, Chapter 8: Waking and sleeping . Fourth edition. Tehran: Ghazal, 1381, p 231.
  3. Blask DE, Wilson ST, Zalatan F. Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. J Cancer Res 1997; 57(10): 1909–14.
  4. Kakizaki M1, Kuriyama SSone TOhmori-Matsuda KHozawa ANakaya N , et al. Nakaya. Sleep duration and the risk of breast cancer: the Ohsaki cohort study. Br J Cancer  2008; 99(9): 1502–1505.
  5. Lehrer S, Green S, Ramanathan L, Rosenzweig KE. Insufficient sleep associated with increased breast cancer mortality Sleep Med  2013; 14(5):469.
  6. Reinoso-Suárez F, de Andrés I, Garzón M. Functional anatomy of the sleep-wakefulness cycle: wakefulness. Adv Anat Embryol Cell Biol 2011; 208: 1-128.
  7. Kalsbeek A, van der Spek R, Lei J, Endert E, Buijs RM, Fliers E. Circadian rhythms in the hypothalamo-pituitary-adrenal (HPA) axis. Mol Cell Endocrinol  2012; 349(1): 20-9.
  8. Bittman EL, Doherty L, Huang LY, Paroskie A. Period gene expression in mouse endocrine tissues. Am J Physiol Regul Integr Comp Physiol 2003; 285(3): R561–R569.
  9. Chung S, Son Gh, Kim K. Circadian rhythm of adrenal glucocorticoid: its regulation and clinical implication. Biochim Biophys Acta 2011; 1812(5): 581–591.
  10. Cho K, Ennaceur A, Cole JC, Suh CK. Chronic jet lag produces cognitive deficits. J  Neurosci  2000; 20(6): RC661–5.
  11. Oishi K, Amagai N, Shirai H, Kadota K, Ohkura N, Ishida N. Genome-wide expression analysis reveals 100 adrenal gland-dependent circadian genes in the mouse liver. DNA Res 2005; 12(3): 191–202.
  12. Kiessling S, Eichele G, Oster H. Adrenal glucocorticoids have a key role in circadian resynchronization in a mouse model of jet lag. J Clin Invest 2010; 120(7): 2600–09.
  13. Hellman L, Nakada F, Curti J, Weitzman ED, Kream J, Roffwarg H, et al. Cortisol is secreted episodically by normal man. J Clin Endocrinol Metab 1970; 30(4): 411–22.
  14. Gallagher TG, Yoshida K, Roffwarg HD, Fukushima DK, Weitzman ED, Hellman L. ACTH and cortisol secretory patterns in man. J Clin Endocrinol Metab 1973; 36(6): 1058–68.
  15. Chrousos GP. The hypothalamic– pituitary– adrenal axis and immune mediated inflammation. N Engl J Med 1995; 332(20): 1351– 62.
  16. Het S, Ramlow G, Wolf OT. A meta-analytic review of the effects of acute cortisol dministration on human memory. Psychoneuroendocrinology 2005; 30(8):771–84.
  17. Chan S, Debono M. Replication of cortisol circadian rhythm: new advances in hydrocortisone replacement therapy. Therapeutic Advances in Endocrinology and Metabolism 2010; 1(3): 129-38.
  18. Federenko I, Wüst S, Hellhammer DH, Dechoux R, Kumsta R, Kirschbaum C. Free cortisol awakening responses are influenced by awakening time. Psychoneuroendocrinology 2004; 29(2):174–84.
  19. Williams E, Magid K, Steptoe A. The impact of time of waking and concurrent subjective stress on the cortisol response to awakening. Psychoneuroendocrinology 2005; 30(2):139–48.
  20. Fries E, Dettenborn L, Kirschbaum C. The cortisol awakening response (CAR): facts and future directions. Int J Psychophysiol 2009; 72(1): 67–73.
  21. Berride CW, Isaac so, Espana RA. Additive wake-promoting actions of medial basal forebrain noradrenergic alpha-and beta-recoptor stimulation. Behav neurosci 2003; 117(2):350-9.
  22. Prata Lima MF, Baracat EC, Simões MJ. Effects of melatonin on the ovarian response to pinealectomy or continuous light in female rats: similarity with polycystic ovary syndrome. Braz J Med Biol Res 2004; 37(7): 987-95.
  23. Valkenburg O, Uitterlinden AG, Themmen AP, de Jong FH, Hofman A, Fauser BC, et al. Genetic polymorphisms of the glucocorticoid receptor may affect the phenotype of women with anovulatory polycystic ovary syndrome. Hum Reprod 2011; 26(10):2902-11.
  24. Zangeneh FZ, Mohammadi A, Ejtemaeimehr Sh, Naghizadeh MM, Aminee F. The role of opioid system and its interaction with sympathetic nervous system in the processing of polycystic ovary syndrome modeling in rat  Arch Gynecol Obstet 2011; 283(4):885–892.
  25. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011; 16(2):CD007506.
  26. Fleming R, Hopkinson ZE, Wallace AM, Greere IA, Sattar N. ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo- controlled trial. J Clinical Endocrinol Metab 2002; 87(2): 569-74.
  27. Rebar R. Judd HL. Yen SS. Rakoff J. Vandenberg G. Naftoline F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976; 57(5): 1320-9.
  28. Lobo RA. Kletzky Oa. Campeau JD. Dizerega GS. Elevated bioactive luteinizing hormone in women with polycystic ovary system. Fertil Steril 1981; 39(5):674-8.
  29. Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod  2003; 19(1): 41 –7.
  30. Bazaz Sh, Eissa M. Human updates, communication quality of sleep, quality of life, with some blood parameters in patients on maintenance dialysis therapy. Journal of Medical Sciences, Winter 1386, 9 (4): 74-67.
  31. Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28(2): 193-213.
  32. Maquet P. Sleep function(s) and cerebral metabolism. Behav Brain Res 1995; 69 (1–2): 75-83.
  33. Steiger A. Sleep and the hypothalamo–pituitary–adrenocortical system. Sleep Med  Rev 2002; 6(2): 125–138.
  34. Peters A, Schweiger U, Pellerin L, Hubold C, Oltmanns KM, Conrad M, et al. The selfish brain: competition for energy resources. Neurosci Biobehav Rev 2004; 28(2): 143–80.
  35. Dimitrov S, Lange T, Benedict C, Nowell MA, Jones SA, Scheller J, et al. Sleep enhances IL-6 trans-signaling in humans. FASEB J 2006; 20 (12): 2174–76.
  36. Caraty A, Grino M, Locatelli A, Guillaume V, Boudouresque F, Conte-Devoix B, et al. Insulin-induced hypoglycemia stimulate corticotropin-releasing factor and arginine vasopressin secretion into hypophyseal portal blood of conscious, unrestrained rams. J Clin Invest 1990; 85(6):1716-21.
  37. Pasquali R, Gambineri A. Cortisol and the Polycystic Ovary Syndrome. Expert Rev Endocrinol Metab 2012; 7: 555-566.
  38. Miller DB, O'Callaghan JP. Neuroendocrine aspects of the response to stress. Metabolism 2002; 51(6 Suppl 1): 5-10.
  39. Dahlgrene E, Janson PO, Jahansson S, Lapidus L, Lindstedt G, Tengborn L. Hemostatic and metabolic variable in women with polycystic ovary syndrome. Fertil Steril 1994; 61(3):455-60.
  40. Milutinović DV, Macut D, Božić I, Nestorov J, Damjanović S, Matić G. Hypothalamic-pituitary-adrenocortical axis hypersensitivity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2011; 119(10):636-43.
  41. Sverrisdottir YB, Mogrent T, Kataoka J, Janson PO, Stener-Victorin E. Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth?. Am J Physiol Endocrinol Metab 2008; 294(3):E576–81.
  42. Zangeneh FZ, Mohammadi A, Ejtemaeimehr Sh, Naghizadeh MM, Aminee F. The role of opioid system and its interaction with sympathetic nervous system in the processing of polycystic ovary syndrome modeling in rat. Arch Gynecol Obstet 2011; 283(4):885–892.
  43. Zafari Zangeneh F,  Naghizadeh MM, Abedinia N, Haghollahi F,  Hezarehei D. Psychological Signs in Patients with Polycystic Ovary Syndrome. Journal of Family and Reproductive Health 2012; 6(4):145-51.